Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Rheumatologist: February 2021

okawa somchai / shutterstock.com

Case Report: A Lupus Patient with Abdominal Pain

Emily Purcell, MD, Colin Ligon, MD, MHS, & Chris T. Derk, MD, MS  |  February 16, 2021

Our patient was a 33-year-old, 5’2″ Asian woman with a past medical history of systemic lupus erythematosus (SLE). The diagnosis was based on serologies positive for anti-nuclear antibodies (ANAs), as well as antibodies to Sm, RNP and SSA. Her illness included neuropsychiatric and cutaneous involvement. She also had a diagnosis of Hashimoto’s thyroiditis.  She presented…

Point-of-Care Testing for COVID-19

Philip Seo, MD, MHS  |  February 16, 2021

Ethan Craig was not pleased. As a reader of this column, you know that Dr. Craig is an assistant professor of clinical medicine in the Division of Rheumatology at the University of Pennsylvania and an associate editor of The Rheumatologist. On this particular morning, however, he was the father of a 5-year-old who woke up…

The Character of Rheumatology Has Changed Over the Past 50 Years

Bruce Rothschild, MD  |  February 16, 2021

Camelot allegedly existed once upon a time in South Wales. The name was evoked again in the 1960s, but perhaps it is also applicable to the character of rheuma­tology in the halcyon days of the 1970s and 80s.  That’s not to belittle the world we now live in, with so many treatment options for our…

Lost and found

The History of ACE Inhibitors in Scleroderma Renal Crisis

Ruth Jessen Hickman, MD  |  February 16, 2021

Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

The ARP Revises Its Fundamentals of Rheumatology Course

Hiral Master, PT, PhD, MPH, Teresa J. Brady, PhD, Aileen Ledingham, PT, MS, PhD, & Carole Dodge, OT, CHT, on behalf of the ARP eLearning Subcommittee  |  February 16, 2021

The ARP’s revised Fundamentals of Rheumatology Course (FRC) will soon be released on the ACR website. The course was revamped by interdisciplinary rheuma­tology professionals emphasizing an inter-professional approach to patient care. It is intended to reach a broad audience, including nurses, occupational therapists, pharmacists, physical therapists, psychologists and social workers to name a few. However,…

The Effects of IL-17A Inhibitors on the Microbiota

Vanessa Caceres  |  February 16, 2021

The use of an interleukin (IL) 17A inhibitor resulted in gut microbial dysbiosis and features of subclinical intestinal inflammation in a subgroup of psoriatic arthritis (PsA) and spondyloarthritis (SpA) patients, according to a multidisciplinary, collaborative study across several institutions published in Arthritis & Rheumatology.1 Understanding the downstream effects of these perturbations is an important step…

Updated Clinical Practice Guidelines for Lyme Disease, Lyme Arthritis

Elizabeth Hofheinz, MPH, MEd  |  February 16, 2021

A team of healthcare practitioners and researchers, spearheaded by the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN) and the ACR, has developed updated evidence-based clinical practice guidelines for the prevention, diagnosis and treatment of Lyme disease. The 2020 guidelines cover a wide variety of Lyme disease manifestations, including Lyme arthritis. Linda…

The Unapproved-Drugs Initiative Is Coming to an End

Jason Melehani, MD, PhD  |  February 16, 2021

On Friday, Nov. 20, 2020, the U.S. Department of Health and Human Services (HHS) published a Notice through the Federal Register announcing the withdrawal of guidance documents that established the Unapproved Drugs Initiative. This Notice brings to an end a 14-year-old program that has been blamed for significantly contributing to the rising cost of some…

A New $1 Million Endowed Chair Honors Dr. Richard M. Silver

Catherine Bennett  |  February 16, 2021

The Medical University of South Carolina (MUSC), Charleston, has established a $1 million endowed chair to support world-class autoimmune research and scholarship. The Silver chair is a tribute to the distinguished career and contributions of former Rheumatology & Immunology Division Director Richard M. Silver, MD, MACR, distinguished university professor and active division member. The inaugural holder…

Research Coordinators Offer a Lot to Clinical Rheumatology Research Teams

Donah Zack Crawford, MA, & Jeff Newcomb, BA  |  February 16, 2021

COVID-19 is responsible for many things, including pla­cing public attention on clinical trials and the worldwide race to approve a vaccine. The words rushed to market usually strike fear in the minds and hearts of clinical research coordinators. Many have seen investigational products with aggressive timelines withdrawn mid-study or during late-stage trials. This year, we…

Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

William J. Scheuing, MD, Nitasha Kumar, MD, William Davis, MD, & Robert Quinet, MD  |  February 16, 2021

Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

Study Finds Renal Arteriosclerosis Is Common in Lupus Nephritis Patients

Mary Beth Nierengarten  |  February 16, 2021

Renal arteriosclerosis is common in lupus patients with nephritis and occurs two decades earlier than it does in people without lupus nephritis (LN), report investigators in a study that examined the prevalence of renal arteriosclerosis in LN patients compared with healthy controls.1  The finding suggests that renal arteriosclerosis could be used as a biomarker for…

Diagnostic Drill-Down: New Research Suggests Genetic Autoinflammatory Roots

Mary Beth Nierengarten  |  January 25, 2021

Two experts discussed ongoing difficulties in diagnosing autoinflammatory disease, & promising new studies that point to possible genetic roots of autoinflammatory disease.

Late-Breaking Abstract Session Spans the Realm of Drug-Related Research

Vanessa Caceres  |  January 25, 2021

In the late-breaking abstract session at ACR Convergence 2020, drug research for a variety of indications is reviewed.

MRI & Axial Spondyloarthritis: Experts Discuss Controversies in the Diagnostic Evaluation of axSpA

Lara C. Pullen, PhD  |  January 25, 2021

Three experts discuss the ins and outs of using magnetic resonance imaging to diagnose axial spondyloarthritis, particularly in individuals who lack clear clinical symptoms indicative of disease.

Smart, Stem Cell-Based Implants May Revolutionize the Treatment of Arthritis

Lara C. Pullen, PhD  |  January 25, 2021

Recent breakthroughs in stem cell-based treatments for arthritis may help delay joint replacement for some patients. Farshid Guilak, PhD, described the methods for creating bioartificial cartilage, its implications for inflammation, disease flare and more.

B Cell Depletion: The Latest Information on Disease Processes, Therapies

Lara C. Pullen, PhD  |  January 25, 2021

Experts discussed the latest knowledge on B cell disease processes, and what it might mean for future B cell depletion therapies.

Tell a Convincing Story: Tips from the Experts on How to Secure Research Grants

Thomas R. Collins  |  January 22, 2021

Speakers at ACR Convergence 2020 offered a range of tips to navigate the competitive environment of research funding, emphasizing the importance of collaboration, diversifying funding sources and staying determined in the face of disappointment.

ACR Convergence 2020

Interfering with Interferon: Experts Discuss IFN Signaling & IFN Inhibition Treatment Possibilities

Mary Beth Nierengarten  |  January 25, 2021

NIH investigators describe key features and genetic causes of Mendelian interferonopathies, & treatment approaches that may indicate the efficacy of IFN inhibition.

The Psychosocial Toll of COVID-19

Thomas R. Collins  |  January 25, 2021

Experts discussed the heavy toll the pandemic has taken on patients and clinicians, with many patients in need of mental health support and others in need of rehabilitation.

Case Report: Drug-Induced Lupus & ANCA-Associated Vasculitis Overlap

Mohammad A. Ursani, MD, RhMSUS, Ojas Naik, MD, Rohaan Khan & William F. Glass II, MD, PhD  |  February 16, 2021

Drug-induced lupus erythe­matosus and ANCA-associated vasculitis (AAV) are both autoimmune conditions associated with the use of hydralazine, a commonly prescribed drug for hypertension and congestive heart failure. Although the pathogenesis is unknown, it is believed that hydralazine alters neutrophil and lymphocyte function and promotes exposure of antigens, leading to the development of anti-neutrophil antibodies (ANCA)…

Study Finds NSAIDs Raise Heart Disease Risk in Osteoarthritis Patients

Susan Bernstein  |  February 16, 2021

In a controlled, large-cohort, longi­tudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1  This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the…

The ACR’s 2020 Advocacy Year in Review

Blair Solow, MD, & Zachary Wallace, MD, MSc  |  February 16, 2021

To say it has been an interesting (the science and the memes), tumultuous (the politics) and heartbreaking (the pandemic and social injustice) year is an understatement. There have been moments of grace and inspiration that we hope have kept everyone going.  As we look to 2021, we take lessons from our experiences in 2020. Washington,…

Reporting & Other Tips for the CARES Act Provider Relief Fund

Steven M. Harris, Esq.  |  February 16, 2021

Between April and December 2020, many eligible healthcare providers received or applied for payments from the $175 billion Coronavirus Aid, Relief and Economic Security (CARES) Act Provider Relief Fund (PRF) through the U.S. Department of Health & Human Services (HHS). On Dec.27, 2020, the Consolidated Appropriations Act, 2021 (the Appropriations Act) was signed into law,…

Rheum After 5: Dr. Angus Worthing, the Singing Rheumatologist

Carol Patton  |  February 16, 2021

Every Christmas Eve, Angus Worthing, MD, FACP, FACR, his wife, Margaret, and two young children, engage in a sing-off over the phone, competing against a professional quartet comprising his best friend, Doug, Doug’s sister and their parents. Dr. Worthing, a partner at Arthritis & Rheumatism Associates in Washington, D.C., demonstrated his musical talent as a…

Risankizumab May Improve Symptoms of PsA

Michele B. Kaufman, PharmD, BCGP  |  January 21, 2021

Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.

Hydroxychloroquine Cardiotoxicity in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  January 5, 2021

Hydroxychloroquine may not increase the risk of cardiotoxicity in RA patients, according to findings presented during ACR Convergence 2020.

Issue Archive

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences